SCHEMBL15428757

SCHEMBL15428757

Cc1ccc(Cl)c(-n2nc(C)cc2N)c1

nearest known ligand 0.54

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 4/20 0.53
POLB P06746 3/20 0.50
CYP1A2 P05177 3/20 0.49
CYP2C19 P33261 3/20 0.49
MAPK1 P28482 1/20 0.49
MEN1 O00255 2/20 0.45
KMT2A Q03164 2/20 0.45
LMNA P02545 3/20 0.44
SMN1; SMN2 Q16637 5/20 0.43
RAB9A P51151 4/20 0.43
CYP3A4 P08684 2/20 0.43
CYP2C9 P11712 2/20 0.43
PKM P14618 1/20 0.40
MAPT P10636 2/20 0.40
NPC1 O15118 1/20 0.38
TP53 P04637 1/20 0.38
TSHR P16473 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL11334891 0.87 CYP1A2 (0.49) ALDH1A1POLBCYP1A2CYP2C19MAPK1
SCHEMBL9193897 0.84 CYP1A2 (0.46) ALDH1A1POLBCYP1A2CYP2C19MAPK1
SCHEMBL3304391 0.83 ALDH1A1 (0.56) ALDH1A1POLBCYP1A2CYP2C19MAPK1
SCHEMBL1817147 0.81 CYP1A2 (0.59) ALDH1A1POLBCYP1A2CYP2C19MAPK1
SCHEMBL15428642 0.80 CRHBP (0.48) ALDH1A1POLBCYP1A2CYP2C19MAPK1
SCHEMBL15428697 0.80 KDM4E (0.44) ALDH1A1POLBCYP1A2CYP2C19MAPK1
SCHEMBL7894799 0.78 ALDH1A1 (0.48) ALDH1A1POLBCYP1A2CYP2C19MAPK1
SCHEMBL11326122 0.78 LMNA (0.53) ALDH1A1POLBCYP1A2CYP2C19MAPK1
SCHEMBL15428755 0.77 L3MBTL1 (0.41) ALDH1A1CYP2C19MEN1KMT2ARAB9A
SCHEMBL11652491 0.77 LMNA (0.51) ALDH1A1POLBCYP1A2CYP2C19MAPK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20160244456-A1 PYRAZOLOPYRIMIDINE JAK INHIBITOR COMPOUNDS AND METHODS GENENTECH, INC. (US) 2016-08-25 US disclosed
EP-2962566-A1 PYRAZOLOPYRIMIDINE JAK INHIBITOR COMPOUNDS AND METHODS Genentech, Inc. (US) 2016-01-06 EP disclosed
EP-2348860-B1 PYRAZOLOPYRIMIDINE JAK INHIBITOR COMPOUNDS AND METHODS GENENTECH INC (US) 2015-05-27 EP disclosed
US-20140107099-A1 PYRAZOLOPYRIMIDINE JAK INHIBITOR COMPOUNDS AND METHODS GENENTECH, INC. (US) 2014-04-17 US disclosed
US-8637526-B2 Pyrazolopyrimidine JAK inhibitor compounds and methods GENENTECH, INC. (US) 2014-01-28 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140107099-A1 PYRAZOLOPYRIMIDINE JAK INHIBITOR COMPOUNDS AND METHODS JAK2, JAK1, JAK3 ALDH1A1 1236/4885POLB 2697/4885CYP1A2 575/4885
US-20160244456-A1 PYRAZOLOPYRIMIDINE JAK INHIBITOR COMPOUNDS AND METHODS JAK2, JAK1, JAK3 ALDH1A1 1236/4885POLB 2697/4885CYP1A2 575/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.